Company Profile
Absci Corporation Stock Price, News & Catalysts
- Ticker:
- ABSI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
9.50 USD (+0.96%)
Close
Last updated: August 12, 2026
990M USD
Market cap
Why the stock is moving
The latest company update was “Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results”. ABSI changed 0.96% and closed at $9.50 on Aug 12, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
AI-Enabled Biologic Design
Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models.
ABS-201
ABS-201 is a long-acting antibody against the prolactin receptor. Its pharmacokinetic profile is intended to support only a few injections over a six-month treatment period.
Pattern Hair Loss
The Phase 1/2a HEADLINE study evaluates ABS-201 as a potentially durable treatment for male and female pattern hair loss through a mechanism distinct from existing therapies.
Endometriosis
Absci is also advancing ABS-201 as a potential non-sex-steroid, disease-modifying treatment that could address both pain and lesion growth in endometriosis.
Prolactin-Focused Pipeline
ABS-202 is a second anti-prolactin-receptor antibody in preclinical development for an undisclosed inflammatory and immunologic indication, extending the company's internal prolactin biology franchise.
Future catalysts
- Interim proof-of-concept data from the HEADLINE study of ABS-201 in pattern hair loss in the second half of 2026.
- Initiation of a Phase 2 study of ABS-201 in endometriosis in the fourth quarter of 2026.
- Full proof-of-concept data from HEADLINE in early 2027.
- Potential proof-of-concept data from the Phase 2 endometriosis study in the second half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Absci Corporation (ABSI)?
Absci Corporation (ABSI) most recently closed at 9.50 USD, a +0.96% move versus the previous session.
What is the market cap of Absci Corporation (ABSI)?
Absci Corporation currently has a market capitalization of 990M USD on BioPharmSignal.
What does Absci Corporation do?
AI-Enabled Biologic Design Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models. ABS-201 ABS-201 is a long-acting antibody against the prolactin receptor. Its pharmacokinetic profile is...
On which exchange is ABSI stock listed?
Absci Corporation (ABSI) is associated with NASDAQ, United States, Biopharma.
What is ABS-201?
Interim proof-of-concept data from the HEADLINE study of ABS-201 in pattern hair loss in the second half of 2026.
Which conditions is Absci Corporation targeting with ABS-201?
Interim proof-of-concept data from the HEADLINE study of ABS-201 in pattern hair loss in the second half of 2026.
How does Absci Corporation describe recent progress with ABS-201?
Interim proof-of-concept data from the HEADLINE study of ABS-201 in pattern hair loss in the second half of 2026.
What is ABS-202?
Prolactin-Focused Pipeline ABS-202 is a second anti-prolactin-receptor antibody in preclinical development for an undisclosed inflammatory and immunologic indication, extending the company's internal prolactin biology franchise.